Tumor News and Research

RSS

Sunesis Pharmaceuticals presents data of Voreloxin in patients with acute myeloid leukemia and ovarian cancer

Sunesis Pharmaceuticals, Inc. presented data from three clinical trials of the company's lead drug candidate, voreloxin (formerly SNS-595), at the Chemotherapy Foundation Symposium held in New York on November 4-8.

7 Nov 2008

Alteration of a gene causes neuroblastoma

Olivier Delattre's team (Inserm Unit 830 "Genetics and Biology of Cancer") of the Institut Curie reveal in an article in the 16 October issue of Nature that alteration of the ALK gene is closely associated with the most frequent solid extracerebral tumor in children-neuroblastoma. By studying the familial forms of this tumor, the researchers also conclude that ALK is a gene that predisposes to neuroblastoma.

7 Nov 2008

Scientists at MIT create backpacks for cells which deliver chemotherapy agents

MIT engineers have outfitted cells with tiny "backpacks" that could allow them to deliver chemotherapy agents, diagnose tumors or become building blocks for tissue engineering.

7 Nov 2008

Scientists sequence genome of a cancer patient

For the first time, scientists have decoded the complete DNA of a cancer patient and traced her disease - acute myelogenous leukemia - to its genetic roots.

6 Nov 2008

Therapy targeting cyclin D1 protein may block expansion of breast cancer cells

Breast cancer stem cells are known to be involved in therapy resistance and the recurrence of cancerous tumors.

6 Nov 2008

Anti-brain tumor agent derived from herpes virus passes next hurdle

An anti-brain tumor agent developed from a genetically engineered herpes simplex virus has been shown to be safe when given in two doses and injected directly into the brain of patients with malignant glioma.

6 Nov 2008

10 symptoms that should never be ignored

Not every ache and pain merits a quick trip to the doctor -- but some do.

6 Nov 2008

Call to explore broader use of human papillomavirus vaccines

A call to explore a broader use of HPV (human papillomavirus) vaccines and the validation of a simple oral screening test for HPV-caused oral cancers are reported in two studies by a Johns Hopkins Kimmel Cancer Center investigator.

4 Nov 2008

Rare immune cell may help those with Crohn's and colitis

The tonsils and lymphoid tissues in the intestinal tract that help protect the body from external pathogens are the home base of a rare immune cell newly identified by researchers at Washington University School of Medicine in St. Louis.

4 Nov 2008

Just one mutated SMAD4 allele is enough to cause cancer

Tumour suppressor genes do not necessarily require both alleles to be knocked out before disease phenotypes are expressed.

4 Nov 2008

Human papillomavirus helps cervical and head and neck cancers resist treatment and grow and spread

The human papillomavirus (HPV) allows infected cervical and head and neck cancer cells to maintain internal molecular conditions that make the cancers resistant to therapy and more likely to grow and spread, resulting in a poor prognosis for patients, researchers with UCLA's Jonsson Cancer Center found.

4 Nov 2008

Scientist says research indicates need for effective HPV vaccine for women and men and a simple HPV screening test

3 Nov 2008

Genentech submits application to FDA for Avastin in the most aggressive form of brain cancer

Genentech has announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Avastin (bevacizumab) as a therapy for people with previously treated glioblastoma. If accepted by the FDA, the application would be considered for an accelerated approval that allows provisional approval of medicines for cancer or other life-threatening diseases based on preliminary evidence suggesting clinical benefit.

3 Nov 2008

Double-barreled immune cell approach for neuroblastoma

Adding an artificial tumor-specific receptor to immune system cells called T-lymphocytes that target a particular virus extended and improved the cells' ability to fight a form of childhood cancer called neuroblastoma, said researchers form Baylor College of Medicine and Texas Children's Hospital in a report that appears online in the journal Nature Medicine.

2 Nov 2008

Research points to new treatment options for infantile hemangioma

A team of researchers led by Harvard School of Dental Medicine (HSDM) Dean for Research Bjorn Olsen has discovered a mechanism for the rapid growth seen in infantile hemangioma, the most common childhood tumor.

31 Oct 2008

Gleevec holds potential as first drug to successfully treat neurofibromatosis

Researchers at the Indiana University School of Medicine report that the anti-cancer drug Gleevec holds out promise to become the first effective treatment for neurofibromatosis, a genetic disease that has resisted treatments until now.

30 Oct 2008

Discovery of mechanism and possible drug treatment for growth of nerve tumors in neurofibromatosis

Researchers studying neurofibromatosis type 1 - a rare disease in which tumors grow within nerves - have found that the tumors are triggered by crosstalk between cells in the nerves and cells in the blood.

30 Oct 2008

Cancer requires support from immune system to develop, researchers report

Tumors that grow around nerves in a rare genetic disease need cooperation from cells from the immune system in order to grow, reports a team of scientists, including researchers from UT Southwestern Medical Center.

30 Oct 2008

Researchers discover how Sonic hedgehog gene controls brain development

University of Pennsylvania School of Medicine researchers have discovered how the expression of the Sonic hedgehog gene is regulated during brain development and how mutations that alter this process cause brain malformations. The results appear online this month in Nature Genetics.

28 Oct 2008

Sunesis Pharmaceuticals updates clinical data on Voreloxin in platinum-resistant ovarian cancer

Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.

27 Oct 2008